Balaji Amines (530999) Stock Overview
Engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
530999 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorCA$5.07FV • 68.0% undervalued intrinsic discount
4849.4%Revenue growth p.a.
13.4k
37
1
271
Balaji Amines Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,331.85 |
| 52 Week High | ₹1,946.00 |
| 52 Week Low | ₹905.15 |
| Beta | 0.44 |
| 1 Month Change | 30.46% |
| 3 Month Change | 19.15% |
| 1 Year Change | 5.46% |
| 3 Year Change | -39.92% |
| 5 Year Change | -44.56% |
| Change since IPO | 10,525.05% |
Recent News & Updates
530999: Higher Revenue Outlook And Lean Margins Will Support Future Upside
Analysts have trimmed their price target for Balaji Amines from ₹1,616.67 to ₹1,447.50, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair Value: Trimmed from ₹1,616.67 to ₹1,447.50, indicating a lower central estimate for the share price.
530999: Higher Margin Outlook And Upcoming Results Will Support Bullish Repricing
Analysts have kept the price target for Balaji Amines steady at ₹1,561, citing slightly adjusted assumptions on the discount rate, revenue growth, profit margin and forward P/E as the main factors behind the unchanged view. What's in the News A board meeting is scheduled for January 29, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
530999: Refined Margins And P E Assumptions Will Likely Support Returns
Analysts have maintained their fair value estimate for Balaji Amines at ₹1,334. The steady price target is supported by only small adjustments to the discount rate, revenue growth assumptions, profit margin and future P/E expectations.530999: Refined Margins And P E Assumptions Will Likely Support Returns
Analysts have kept their fair value estimate for Balaji Amines steady at ₹1,334, with small refinements to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this unchanged price target. What's in the News A board meeting is scheduled on Jan 29, 2026 to consider, approve and take on record the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).530999: Higher Future P E And Margins Will Likely Support Returns
Analysts have maintained their price target for Balaji Amines at ₹1,334, reflecting a balance between a lower discount rate, slightly adjusted revenue growth assumptions, a modestly higher profit margin outlook, and a marginally higher future P/E multiple. What's in the News Board meeting scheduled for January 29, 2026, to review and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025.530999: Higher Margin Outlook And Upcoming Results Will Support Bullish Repricing
Analysts have revised their price target for Balaji Amines from ₹2,331 to ₹1,561, reflecting updated views on a lower assumed revenue growth rate, a slightly higher discount rate, a higher profit margin, and a reduced future P/E multiple. What's in the News Board meeting scheduled for Jan 29, 2026, to review and approve the unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Recent updates
530999: Higher Revenue Outlook And Lean Margins Will Support Future Upside
Analysts have trimmed their price target for Balaji Amines from ₹1,616.67 to ₹1,447.50, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair Value: Trimmed from ₹1,616.67 to ₹1,447.50, indicating a lower central estimate for the share price.530999: Higher Margin Outlook And Upcoming Results Will Support Bullish Repricing
Analysts have kept the price target for Balaji Amines steady at ₹1,561, citing slightly adjusted assumptions on the discount rate, revenue growth, profit margin and forward P/E as the main factors behind the unchanged view. What's in the News A board meeting is scheduled for January 29, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).530999: Refined Margins And P E Assumptions Will Likely Support Returns
Analysts have maintained their fair value estimate for Balaji Amines at ₹1,334. The steady price target is supported by only small adjustments to the discount rate, revenue growth assumptions, profit margin and future P/E expectations.530999: Refined Margins And P E Assumptions Will Likely Support Returns
Analysts have kept their fair value estimate for Balaji Amines steady at ₹1,334, with small refinements to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this unchanged price target. What's in the News A board meeting is scheduled on Jan 29, 2026 to consider, approve and take on record the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).530999: Higher Future P E And Margins Will Likely Support Returns
Analysts have maintained their price target for Balaji Amines at ₹1,334, reflecting a balance between a lower discount rate, slightly adjusted revenue growth assumptions, a modestly higher profit margin outlook, and a marginally higher future P/E multiple. What's in the News Board meeting scheduled for January 29, 2026, to review and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025.530999: Higher Margin Outlook And Upcoming Results Will Support Bullish Repricing
Analysts have revised their price target for Balaji Amines from ₹2,331 to ₹1,561, reflecting updated views on a lower assumed revenue growth rate, a slightly higher discount rate, a higher profit margin, and a reduced future P/E multiple. What's in the News Board meeting scheduled for Jan 29, 2026, to review and approve the unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).530999: Richer Forward P/E Will Likely Support Returns Despite Thinner Margins
Analysts have raised their price target for Balaji Amines from ₹1,185 to ₹1,334, reflecting revised assumptions of higher revenue growth and a richer forward P/E multiple, partly offset by a lower profit margin outlook and a slightly higher discount rate. What's in the News Board meeting scheduled on Jan 29, 2026, to consider, approve and take on record the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).530999: Stable Margins And Upcoming Results Will Support Further Upside
Analysts have maintained their price target for Balaji Amines at ₹1,616.67, reflecting largely unchanged assumptions on the discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for November 10, 2025, to consider and approve the unaudited standalone financial results for the quarter and half year ended September 30, 2025 (company filing).530999 Will Likely See Slower Expansion Offset By Stronger Profit Margins
Analysts have reduced their fair value estimate for Balaji Amines to ₹1,185 from ₹1,598, citing expectations of slower revenue growth and a lower future P E multiple. This is partially offset by improved projected profit margins and a slightly higher discount rate.530999: Stable Margins And Growth Outlook Will Support Further Upside
Analysts have modestly lifted their price target on Balaji Amines to ₹1,616.67 per share, reflecting slightly higher assumed discount rates and steady long term growth and margin expectations that together support a marginally richer valuation multiple. What's in the News Board meeting scheduled on November 10, 2025 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).530999: Rising Profit Margins Will Drive Further Upside Despite Slower Sales
Analysts have revised their price target for Balaji Amines downward from ₹1,847 to ₹1,617. This change is due to expectations of slower revenue growth, even though profit margin projections have improved.New Plant Launches And Certifications Set To Drive Future Operational Efficiency And Revenue Potential
With both the Future P/E and Discount Rate showing only marginal changes, analysts have effectively maintained their valuation outlook for Balaji Amines, resulting in an unchanged consensus price target of ₹1847. What's in the News Board meeting scheduled to consider and approve un-audited standalone and consolidated financial results for the quarter ended 30 June 2025.
New Plant Launches And Certifications Set To Drive Future Operational Efficiency And Revenue Potential
New plant expansions and strategic focus on high-margin products promise revenue growth and improved net margins through enhanced efficiency and diversification.Shareholder Returns
| 530999 | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | 6.5% | 1.1% | 0.4% |
| 1Y | 5.5% | -1.5% | 4.0% |
Return vs Industry: 530999 exceeded the Indian Chemicals industry which returned -1.5% over the past year.
Return vs Market: 530999 exceeded the Indian Market which returned 3.9% over the past year.
Price Volatility
| 530999 volatility | |
|---|---|
| 530999 Average Weekly Movement | 6.1% |
| Chemicals Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: 530999 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 530999's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,169 | Dundurapu Reddy | www.balajiamines.com |
Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India. The company operates in two segments, Chemicals and Hotel. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, acetonitrile, dimethylcarbonate, propylene glycol, and propylene carbonate.
Balaji Amines Limited Fundamentals Summary
| 530999 fundamental statistics | |
|---|---|
| Market cap | ₹43.15b |
| Earnings (TTM) | ₹1.44b |
| Revenue (TTM) | ₹13.83b |
30.0x
P/E Ratio3.1x
P/S RatioIs 530999 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 530999 income statement (TTM) | |
|---|---|
| Revenue | ₹13.83b |
| Cost of Revenue | ₹7.83b |
| Gross Profit | ₹6.00b |
| Other Expenses | ₹4.56b |
| Earnings | ₹1.44b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 44.46 |
| Gross Margin | 43.38% |
| Net Profit Margin | 10.42% |
| Debt/Equity Ratio | 1.5% |
How did 530999 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield23%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/01 07:41 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Balaji Amines Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nilesh Ghuge | HDFC Securities Limited |
| Jay Gandhi | HDFC Securities Limited |
| null null | K.R. Choksey Shares & Securities Private Ltd. |